Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Neuromyelitis Optica Spectrum Disorders (nmosd) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

2 recruiting trials for Neuromyelitis Optica Spectrum Disorders (nmosd). Eligibility criteria explained in plain English.

TrialFinderData lists 2 Neuromyelitis Optica Spectrum Disorders (nmosd) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Third Affiliated Hospital, Sun Yat-Sen University (1), RenJi Hospital (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is CD20/BCMA-directed CAR-T cells (biological, 1 trial).

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
2
Total Trials
2
Recruiting Now
0
Phase 3 Trials
2
Sponsors

Track Neuromyelitis Optica Spectrum Disorders (nmosd) trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07653984

Cohort Study on Neuroimmune Diseases in the Reproductive Age

Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility. Therefore, effective management of...

Sponsor: Third Affiliated Hospital, Sun Yat-Sen UniversityEnrolling: 1001 location
RECRUITINGPhase 1NCT06249438

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients...

Sponsor: RenJi HospitalEnrolling: 301 location

Frequently Asked Questions

There are currently 2 clinical trials for Neuromyelitis Optica Spectrum Disorders (nmosd), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Neuromyelitis Optica Spectrum Disorders (nmosd), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Neuromyelitis Optica Spectrum Disorders (nmosd), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.